Atossa shares jump 55% after 'poison pill' announcement; but who is suitor?
This article was originally published in Clinica
Executive Summary
Breast cancer diagnostic firm Atossa Genetics has adopted a so-called “poison pill” strategy, aimed to deflect hostile takeovers, and seen its stock climb nearly 55%. The firm did not give any details of who might be trying to buy it, and was not available for comment as Clinica went to press. But nonetheless, its share price closed at $1.91 on 22 May, up from $1.24 the previous day.